

# The effect of omega-3 in non-alcoholic fatty liver disease

<b>Submission date</b> 19/05/2010	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 19/05/2010	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 24/08/2016	<b>Condition category</b> Digestive System	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Richard Johnston

**Contact details**  
Nottingham University Hospital  
Wolfson Digestive Diseases Centre  
C Floor, South Block QMC  
Queen's Medical Centre  
Nottingham  
United Kingdom  
NG7 2UH

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**  
7156

# Study information

## Scientific Title

The effect of n-3 polyunsaturated fatty acid (PUFA) supplementation in patients with steatosis due to non-alcoholic fatty liver disease

## Study objectives

Assess the effects of a 3 month PUFA supplementation versus placebo.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Nottingham Research and Ethics Committee 1, 11/03/2008, ref: 08/H0403/14

## Study design

Single centre randomised interventional treatment trial

## Primary study design

Interventional

## Secondary study design

Randomised controlled trial

## Study setting(s)

Hospital

## Study type(s)

Treatment

## Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

## Health condition(s) or problem(s) studied

Topic: Metabolic and Endocrine; Subtopic: Metabolic and Endocrine (all Subtopics); Disease: Metabolic & Endocrine (not diabetes)

## Interventions

58 patients with biopsy proven steatosis due to non-alcoholic fatty liver disease (NAFLD) will be randomised to 3.5 g n-3 polyunsaturated fatty acid (PUFA) or oleic enriched sunflower oil capsules for 3 months.

Follow-up length: 3 months

Study entry: registration and one or more randomisations

## Intervention Type

Drug

## Phase

Not Applicable

**Drug/device/biological/vaccine name(s)**

Fructose, glucose

**Primary outcome measure**

Hepatic steatosis as determined by magnetic resonance imaging (MRI) spectroscopy pre- and post-intervention

Liver fat stores (MR spectroscopy), measured pre- and post-intervention

**Secondary outcome measures**

Measured pre- and post-intervention:

1. Liver biochemistry
2. Lipid profile
3. Insulin resistance
4. Blood pressure
5. Abdominal visceral fat
6. Inflammatory cytokine profile

**Overall study start date**

12/01/2009

**Completion date**

01/12/2009

## **Eligibility**

**Key inclusion criteria**

1. Age greater than 18 years, either sex
2. Liver biopsy showing NAFLD

**Participant type(s)**

Patient

**Age group**

Adult

**Lower age limit**

18 Years

**Sex**

Both

**Target number of participants**

Planned sample size: 58; UK sample size: 58

**Key exclusion criteria**

1. Excessive alcohol intake - greater than 21 units per week in men and greater than 14 in women
2. A further liver disease diagnosis
3. Poorly controlled diabetes - HbA1c greater than 8.0%

4. Pregnancy
5. Cirrhosis
6. Significant inflammation on liver biopsy - classified as a Brunt moderate or severe
7. Life expectancy of less than 2 years
8. Contraindications to MR scanning - pacemaker or metallic foreign body
9. Changes in the dose or initiation of lipid altering medication within the preceeding three months, such as statins, fibrates or systemic steroids
10. Use of n-3 PUFA supplements within the prior 4 months, an adequate washout period

**Date of first enrolment**

12/01/2009

**Date of final enrolment**

01/12/2009

## **Locations**

**Countries of recruitment**

England

United Kingdom

**Study participating centre**

**Nottingham University Hospital**

Nottingham

United Kingdom

NG7 2UH

## **Sponsor information**

**Organisation**

University of Nottingham (UK)

**Sponsor details**

Wolfson Digestive Diseases Centre

South Block, C-Floor

Queens Medical Centre

Derby Road

Nottingham

England

United Kingdom

NG7 2UH

**Sponsor type**

University/education

**Website**

<http://www.nottingham.ac.uk/>

**ROR**

<https://ror.org/01ee9ar58>

## **Funder(s)**

**Funder type**

Charity

**Funder Name**

Association of Medical Research Charities (AMRC) - CORE

## **Results and Publications**

**Publication and dissemination plan**

Not provided at time of registration

**Intention to publish date****Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration